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To build capacity and collaborative research for future cross-national studies in the Asian
and Pacific Islander (API) region, priority research topics were identified and discussed at
the April 2013 Conference to Promote Global Health in Taipei. These topics included: (1)
neuroscience on human immunodeficiency virus (HIV)/hepatitis C virus (HCV) and
amphetamine-type stimulants (ATS), led by Drs Linda Chang, Gene-Jack Wang, and Betty
Tai; (2) ATS and mental health disorders, led by Drs Richard Rawson and Wilson Compton;
and (3) HIV/HCV transmission and social networks, led by Drs Steven Shoptaw and Jacques
Normand. Potential genetic studies spanning these topical areas as well as the importance
of smoking cessation were further discussed, led by Dr Ming Li. Additional priority research
topics were also identified: (4) drug use prevention; and (5) family involvement to improve
treatment adherence and recovery. Workgroups on these topics will be formed to prioritize
research questions within the respective topical area and to determine the next steps. The
ultimate goal of these workgroups is to stimulate collaboration that will eventually lead to
research studies addressing critical issues related to the rising substance abuse and HIV
infection rates in many Asian countries and, at the same time, to advance the scientific
knowledge of substance abuse and HIV infection.
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Global Health is to build capacity and facilitate collaboration
among participating Asian countries and investigators to
develop and conduct research addressing critical substance
abuse and human immunodeficiency virus (HIV) issues in
the Asian region. During the conference, Dr Wilson Compton
[Director of the Division of Epidemiology, Services, and Pre-
vention Research, National Institute on Drug Abuse (NIDA)]
and Dr Jacques Normand (Director of AIDS Research Pro-
gram, NIDA) both presented comprehensive information on
NIDA funding resources and opportunities for training and
research, particularly for international investigators and
studies. Additionally, a suggestion was made to form work-
groups on priority topics on which investigators from the
United States and Asian countries can work together to
formulate research questions, design studies, and carry out
investigations.
Currently, Asian/Pacific Islander (API) countries have
some of the highest rates of opiate, methamphetamine,
alcohol, and tobacco use, as well as the highest rates of HIV
transmission via injection drug use. Substance abuse is not
only having crippling effects on the economies, family
structures, criminal justice systems, and environment in
API countries, but it also increases the prevalence of many
comorbid illnesses, particularly HIV and hepatitis C virus
(HCV). In most countries around the world, the prevalence
of HIV infection is at least 22 times higher amongst those
who inject drugs than the general population [1]. It is esti-
mated that as many as 5 million drug users in Asia are
living with HIV/AIDS, with injection drug use serving as the
primary mode of transmission. HIV/HCV co-infection rates
are rampant among injection drug users (IDUs) in many
parts of Asia. These health risks are exacerbated by a lack
of state-of-the-art interventions, inadequate access to
treatment, the criminalization of drug use, and stigma
associated with both substance use and HIV/AIDS, com-
bined with limited infrastructure and expertise for
addressing these issues on a local, community, and na-
tional level [1].
The tremendous multidisciplinary and world-class exper-
tise and knowledge among the conference presenters and
participants represent a great resource for international col-
laborations and scientific development in Asia. Collaborative
efforts to develop and conduct cross-national studies in Asia
to address Asia-specific problems in substance abuse and HIV
are likely to offer tremendous opportunities and potential for
scientific advancements and benefits to patient care. As an
initial step in forming workgroups, efforts were devoted to
identifying research priorities. Three topics were identified
and discussed in the conference: (1) neuroscience on HIV,
HCV, and amphetamine-type stimulants (ATS); (2) ATS and
mental disorders; and (3) HIV/HCV transmission and social
networks. Additional topics that were further identified
include genetics of substance abuse, tobacco cessation, drug
use prevention, and family involvement in treatment adher-
ence and outcomes.Themany presentations and the discussions at the conference,
consistent with findings in the literature, identified that, in
addition to opioids, the use of ATS (e.g., amphetamine, meth-
amphetamine, and ecstasy) and ketamine are serious drug
problems in Asia. HIV, HCV, andHIV/HCV co-infection resulting
from injection drug use are prevalent and require special atten-
tion.Additionally, family involvement inpatient care is aunique
and important cultural factor influencing Asian communities
and populations and should be included in the research agenda.
2.1. Neuroscience on HIV/HCV and ATS
This discussion was led by Drs Linda Chang, Gene-Jack Wang,
and Betty Tai. The workgroup identified and discussed the
following potential research questions:
(1) Different racial/ethnic groups have different morphometric
measures (e.g., height, weight, proportions). Would it be useful
to develop similar normative data resources for different ethnic/
racial groups that can be used to evaluate future brain disorders,
including drug exposure and drug abuse?
An example of such a shared data resource is the NIDA-
funded Pediatric Imaging Neurocognition and Genetics
(PING) study (principal investigators: Chang, Dale, Ernst, Jer-
nigan, Murray; RC2DA29475). This data resource provides a
good example of this type of collaborative effort because it
spanned many sites and quickly led to several high impact
publications [2e5]. The study, which involved nine sites
across the United States, collected data from approximately
1400 typically developing children aged 3e20 years, and the
data are being shared with the neuroscience community. The
biomedical and demographic data include family medical and
drug use histories (if known), the National Institutes of Health
(NIH) Toolbox (cognitive assessments), high resolution neu-
roimaging [including structural and diffusion magnetic reso-
nance imaging (MRI) and functional MRI], saliva for DNA
extraction and genome-wide association studies (GWAS), and
drug usage data (from the PhenX Toolkit). These data of
typically developing children across the ages provide a very
useful normative dataset that allow scientific questions to be
explored in a large pediatric population across the United
States; in addition, future disease-based studies on this pop-
ulation can be compared and contrasted.
Another example is the IMAGEN study, which is a Euro-
pean research project investigating mental health and risk-
taking behavior (including substance use) in teenagers [6].
The IMAGEN study is a multicenter geneticeneuroimaging
investigation, with longitudinal follow-ups, of nearly 2000 14-
year-olds and their parents from across Europe. The study has
generated a valuable database for secondary analysis.
(2) Do tobacco smoking or drugs of abuse affect brain development
or brain aging differently in the various racial/ethnic groups?
What factors contribute to vulnerability to addiction to tobacco
smoking across the different cultures or different countries?
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cigarette smoking exposure and found that tobacco-exposed
female infants show smaller brain volumes and more brain
metabolite abnormalities than unexposed control females,
whereas the male infants show no group differences [7]. Such
sex differences were also found in rodent studies, which
showed opposite effects of gestational nicotine on gene
expression of myelin-related genes in adolescent male and
female offspring [8]. These findings suggest that prenatal to-
bacco exposure may have lasting epigenetic influences in the
brain structures or function of future generations. Given that
tobacco smoking is popular in Asian regions, research should
examine if tobacco smoking (or drugs of abuse) affect brain
development in the various racial/ethnic groups, as well as
factors related to vulnerability to addiction to tobacco smok-
ing across different cultures or countries.
(3) Which genes or factors contribute to the development of psy-
chosis in psychostimulant users or other drug users? Are they
different across the various racial groups? Are there tools that
can be used or need to be developed cross-culturally to assess and
treat psychosis?
Genetic variations may account for the differential devel-
opment of psychosis in psychostimulant users or other drug
users. Genetic studies comparing various racial/ethnic groups
(e.g., Asians versus Caucasians) will be extremely valuable.
For instance, methamphetamine-induced psychosis is
thought to be more common in Asia, based on earlier studies
from Japan. Several single nucleotide polymorphisms [SNPs;
e.g., in the A2A adenosine receptor gene (ADORA2A) and the
serotonin 6 (5-HT6) receptor gene] were found to be more
prevalent in the Japanese population of methamphetamine-
dependent individuals with psychosis [9,10], some with sex
differences. However, whether such associations are also
present in the Caucasian population is unknown. Having
cross-national studies in order to compare findings may lead
to new insights regarding methamphetamine-induced psy-
chosis, which may have further implications for psychosis
associated with other psychiatric disorders.
(4) How do the different clades of HIV affect the brain? Anecdotal
data show that Type C is less neurovirulent compared to Type B.
Will they affect different racial/ethnic groups differently? Will
these different effects be due to genetic variations? Does the same
genetic polymorphism APOE- 34 have differential impact on brain
disorders in different racial/ethnic groups?
Dr Chang demonstrated how the apolipoprotein E (APOE)-
34 gene, which is known to increase the risk for the develop-
ment of Alzheimer’s disease in older individuals, may
contribute to cognitive dysfunction and brain atrophy in HIV-
infected individuals. In particular, younger HIV patients may
show earlier expression of the deleterious effects of APOE- 34,
with subcortical brain atrophy, whereas seronegative controls
with the same gene may demonstrate larger brain volumes
when they are young but show brain atrophy only in older
ages (i.e., antagonistic pleiotropy) [11]. Because the effects of
APOE- 34 may also be expressed differently in different racial
groups (e.g., affecting Whites more than Blacks on workingmemory and semantic memory [12]), such genetic variations
or other factors could be explored across different racial/
ethnic groups in Asia and the Western countries.
(5) The use of marijuana is “very low” in some Asian countries (it is
possible that it is underreported). Is this due to differences in
genetic vulnerability or to different social/cultural pressures
(e.g., is its very low use in Japan due to the strict laws there?).
Are there different sensitivities to brain cannabinoid receptor
Type 1 or Type 2 among Asians?
The low prevalence of marijuana use in Asia also poses
unique research opportunities. Social/cultural, genetics, and/
or underreporting factors can be explored to learn more about
this phenomenon.
2.2. ATS and mental health disorders
Led by Dr Rawson andDr Compton, three areas of research are
needed to address ATS and mental health disorders.
(1) Genetic factors accounting for variations in psychosis and
amphetamine use
Abuse of amphetamines is widespread in API countries
and populations. It has also been reported that many psy-
chiatric patients use amphetamines. Some evidence suggests
that genetic factors may account for variations in psychosis
for individuals using amphetamines [13]. Research on the
genetics of the response to amphetamine appears to have
great potential to provide explanations for the differential
response to amphetamine (persistency of psychosis, etc.) and
changes in the brain produced by amphetamine.
(2) What implementation models and strategies would provide the
optimal method for addressing prevention and clinical services
needs regarding amphetamines in Asia? What implementation
models and strategies could best help integrate SUD services and
other health services?
Evidence-based prevention, treatment, and other services
aremuch needed to address amphetamine use in Asia, but the
optimal strategies to provide these services in Asia remain to
be identified or developed. Additionally, integration of sub-
stance use disorder (SUD) services and other health services
(e.g., for HIV) may also increase the likelihood of achieving
favorable outcomes. Implementation research in these areas
is needed to optimally address amphetamine and related
problems in Asia.
(3) What epidemiological research strategies can be best adapted to
provide good data on the nature and extent of SUDs and HIV and
identify the most critical populations?
While epidemiological data on the nature and extent of
SUDs and HIV in the Asia region have improved in recent
years, there are still significant data gaps that limit these
countries’ ability to identify and understand the issues that
need to be addressed. To provide good data on the nature and
extent of SUDs and HIV, as well as to identify the most critical
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the most appropriate epidemiological research strategies.
2.3. HIV/HCV transmission and social networks
Led by Dr Shoptaw and Dr Normand, several research ideas
were suggested:
(1) Hepatitis B: Testing Truvada as treatment for HBV and PrEP for
HIV in high risk HBV-positive MSM, particularly in Vietnam.
Chronic hepatitis B is a global public health issue, with 350
million people worldwide infected with the hepatitis B virus
(HBV)d75% of them in Asia [14]. HBV is the leading cause of
chronic hepatitis in API countries, and up to 25% of these
patients will eventually die of liver cirrhosis and its compli-
cations. HIV and HBV co-infection is also frequent in Asian
countries, leading to increased morbidity and mortality in
these regions.
Truvada is a HIV medication that prevents HIV from
altering the genetic material of healthy CD4 cells, and thus
prevents the cells fromproducing newvirus and decreases the
amount of virus in the body. It also has been approved as a
pre-exposure prophylaxis (PrEP) for those confirmed to be
HIV-negative and is used to prevent HIV among those at high
risk for the infection, in conjunction with condoms and other
safer-sexmeasures. Truvada has components that potentially
can treat HBV, but it is not currently approved for the treat-
ment of HBV, because its safety and efficacy have not been
established. It was suggested that testing Truvada as a treat-
ment for HBV and PrEP for HIVmay be an innovative approach
for high risk HBV-positivemenwho have sexwithmen (MSM),
particularly in Vietnam.
(2) HCV/HIV: Combining surveillance and genetic sequencing in
Taiwan among IDU networks.
Another innovative research study that was suggested was
to combine surveillance data with genetic sequencing among
IDU networks. HIV and HCV are global public health problems,
and the burden of these diseases is considerable. IDUs are at
high risk for HIV and HCV infection and transmission. Glob-
ally, approximately 10million IDUs are currently or have been
previously infected with HCV, and four million are infected
with HIV. East Asia is among the regions with the highest
concentrations of HIV- and HCV-infected IDUs. Monitoring
the distribution, evolution, and transmission of HIV-1 and
HCV are critically important in efforts to prevent their spread.
Phylogenetic analysis of HIV and HCV viruses can be
applied among infected IDUs to investigate the genotype dis-
tribution, evolution, and transmission of HIV-1 and HCV
among drug users’ networks. With globalization, the popula-
tion migration between regions presents additional chal-
lenges to accurate and efficient surveillance. Therefore,
international collaborative efforts are critical to address these
important public health issues.
(3) SUD and infectious diseases: Studying community-based SUD
treatment and infectious disease management in primary care
settings.Despite the close connection between SUDs and infectious
diseases, services for treating these disorders or diseases are
often delivered by separate facilities or entities that are often
disconnected. Outcomes might be improved by studying
community-based SUD treatment and infectious disease
management in primary care settings in, for example,
Thailand and Los Angeles.
(4) Methamphetamine and HIV: Studying the brains of
methamphetamine-using HIV-positive/negative people with a
medication (ibudilast) that has strong anti-inflammatory
properties.
Another innovative idea is to test ibudilast among
methamphetamine-using HIV-negative and HIV-positive peo-
ple to study its effects on the brain. Ibudilast is an anti-
inflammatory drug that may have some use in reducing meth-
amphetamine addiction. Given that manymethamphetamine-
dependent users are at high risk for HIV, and HIV serostatus
maycomplicate the response to themedication, itwill becritical
to study the brains of methamphetamine-using HIV-positive/
negative people with this medication.
(5) Secondary data analysis on the SATHCAP regarding modeling of
agent networks and spread of infectious diseases.
The Sexual Acquisition and Transmission of HIV Coop-
erative Agreement Program (SATHCAP) is a multisite study
that was funded by the NIDA and was designed to assess the
role of drug use in the sexual transmission of HIV from
traditional high-risk groups, such as MSM and drug users, to
lower risk groups, such as non-drug-using sexual partners
[15]. This database (accessible at http://www.icpsr.umich.
edu/icpsrweb/NAHDAP/studies/29181) offers a great oppor-
tunity for secondary data analysis. A suggested example
topic was to model agent networks and the spread of infec-
tious diseases.
2.4. Additional topics: genetics, drug use prevention,
and family involvement to improve treatment adherence
and recovery
Noting that genetic studies potentially span the above topical
areas, Dr Ming Li discussed smoking cessation to further
illustrate the importance of genetic studies. Smoking depen-
dence, like other types of addiction, is a world health problem
that costs nearly six million human lives per year [16]. This is
especially true in many Asian countries, where a majority of
men report smoking on a regular basis, although relatively
fewer women smoke cigarettes in Asia compared with the
United States and European countries [17,18]. To identify ge-
netic factors for smoking dependence, significant research
efforts have been made by researchers from many countries
throughout the world.
One of the most significant international collaborative ef-
forts was a recently reported genome-wide meta-analysis of
more than 140,000 participants for smoking, which revealed
multiple loci associated with this behavior [19]. The primary
reason for including somany samples in this study was due to
the fact that smoking dependence is a complex disease that is
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netic effect for each locus. Therefore, in order to identify those
susceptible loci with small effect for smoking dependence or
any other addiction, thousands of samples are required. By
contrast, there is no single research team that is able to collect
so many participants from different geographical locations.
Thus, this requires researchers from different institutions to
work together on a scientific problemwith a common interest.
For example, the genetics studymentioned above consisted of
many authors representing many different institutions and
countries. In addition to the large sample size required for a
genetic study, genetic differences among different ethnic
populations also require researchers from different countries
to collaborate with each other. Although some common sus-
ceptible loci have been identified for smoking dependence
across different ethnic samples in the past, a significant
number of loci appear to be ethnicity-specific. For example,
the association of smoking behavior with several loci in the
nicotinic receptor subunits alpha 5, alpha 3, and beta 4 gene
cluster on chromosome 15 identified from European pop-
ulations [20e22] appears to be less significant in participants
of African and Asian origin [23e25]. Again, this points to the
significance of collaboration among researchers from
different institutions and countries.
Further, we would like to point out although most re-
searchers realize it is important to do collaborative research,
its executionmight not be as easy as it sounds. Many practical
issues such as language differences in scales and measures,
Institutional Review Board (IRB) issues, DNA sharing, and
authorship could arise when one tries to set up such collab-
orations among researchers from different institutions across
different countries. However, all these issues can be resolved
with careful planning and discussion.
Another important research topic is substance use pre-
vention in Asia. Prevention is a cost-effective approach to
improve public health. Yet, very little prevention research for
SUDs has been explored or conducted in the Asian region.
Both resources and infrastructure in the Asian region are
needed to allow the development of SUD prevention research.
During this conference, it was proposed that the development
and application of culturally appropriate SBIRT (screening,
brief intervention, and referral to treatment) in primary care
settings may be needed in API countries.
Numerous studies have demonstrated the importance of
social and family support with regard to patient treatment
compliance and outcomes. Culturally, family factors or sup-
port are highly salient in every aspect of life in Asian com-
munities. Although research studies are limited, there have
been some observations that family involvement may be a
major factor contributing to the superior retention rate for
patients participating in methadone maintenance programs
in Vietnam. Further research may be fruitful to test family
involvement-supported interventions that improve treatment
adherence and recovery in Asian countries.3. Conclusions
The exciting research topics and suggestions shared in the
conference are encouraging and will form the bases for theformation of several workgroups and the planning for future
collaboration in cross-national studies in Asia. It is expected
that these workgroups will stimulate collaborations that will
eventually lead to research studies addressing critical sub-
stance abuse and HIV problems common across the Asian
countries and, at the same time, advance the scientific
knowledge of substance abuse and HIV infection.
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